Share
Print
Transformative Innovations in global health
Details
Location:EU 27
Funding agency:
Grantmaking entity type:Development Institution
Description
Topic updates
10 July 2025
EVALUATION RESULTS (STAGE 1)
Published: 10/01/25
Deadline: 20/03/25
Available budget: EUR 49.100.000
In accordance with the call conditions, the evaluation of the first-stage proposals was made looking only at the criteria 'Excellence' and 'Impact'. The threshold for both criteria was 4. The overall threshold (applying to the sum of the two individual scores) was set for each topic/type of action with separate call-budget-split at a level that allowed the total requested budget of proposals admitted to stage 2 be as close as possible to 3 times the available budget (and not below 2.5 times the budget):
- HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage: 8 points
- HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage: 9 points
The results of the evaluation for each topic are as follows:
|
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage |
|
|
Number of proposals submitted (including proposals transferred from or to other calls) |
106 |
|
Number of inadmissible proposals |
0 |
|
Number of ineligible proposals |
14 |
|
Number of above-threshold proposals |
28 |
|
Total budget requested for above-threshold proposals |
67.074.772,15 € |
Summary of observer report:
The evaluations were in the estimation of both observers impartial, fair and equitable. No issues of confidentiality were seen to arise.
This was, in particular, enabled by a careful selection of experts and recorders as well as ensuring that any experts or recorders with a COI were excluded from the discussions of the proposal in question. The use of the SEP platform for all aspects of the reports (IER, CR and QC) also reinforced the confidentiality of the evaluation.
No issues of non-conformity were observed and the evaluation followed all the applicable rules. The eligibility of proposals was determined by the Unit prior to the assignment of experts to proposals. Any issues of proposals being not being “in scope” were discussed by the experts during the consensus meetings.
We recently informed the applicants about the evaluation results for their proposals.
For questions, please contact applicants@global-health-edctp3.europa.eu
GENERALISED FEEDBACK for successful applicants after STAGE 1
In order to best ensure equal treatment, successful stage 1 applicants do not receive the evaluation summary reports (ESRs) for their proposals, but this generalised feedback with information and tips for preparing the full proposal.
Information & tips
Main shortcomings found in the stage 1 evaluation:
• HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage – stage 1 submissions appeared to face frequent challenges and important shortcomings. Typical observations by the group of experts include:
-The emphasis was the clinical development of treatments and/or diagnostics and the focus on late stage development, which was sometimes missed by applicants.
- Very few proposals offered a compelling approach to linking climate factors to diarrhoeal diseases mitigation and adaptation. Where appropriate, proposals were encouraged to include complementary research components that help to improve the understanding on how diarrhoeal diseases are currently influenced by climate and weather and may be further exacerbated by climate change.
Please note that the all the amounts in the proposal are expressed in EUR.
Join the networking platform and find the right partners and co-funders to maximise the chances of your proposal at the second stage. Discover more and register.
Please bear in mind that your full proposal will now be evaluated more in-depth and possibly by a new group of outside experts.
Please make sure that your full proposal is consistent with your short outline proposal. It may NOT differ substantially. The project must stay the same.
25 April 2025
Call HORIZON-JU-GH-EDCTP3-2025-04-two-stage_stage1 has closed on the 20/03/2025.
106 proposals have been submitted.
The breakdown per topic is:
• HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage: 106 proposals
Evaluation results are expected to be communicated in July 2025.
Transformative Innovations in global health
TOPIC ID: HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage
Type of grant: Call for proposals
General information
Programme: Horizon Europe (HORIZON)
Call: Global collaborative action tackling Diarrhoeal Diseases in the context of Climate and Health (HORIZON-JU-GH-EDCTP3-2025-04-two-stage)
Type of action: HORIZON-JU-RIA HORIZON JU Research and Innovation Actions
Type of MGA: HORIZON Action Grant Budget-Based [HORIZON-AG]
Status: Forthcoming
Deadline model: two-stage
Planned Opening Date: 30 January 2025
Deadline dates:
20 March 2025 17:00 (Brussels time)
02 September 2025 17:00 (Brussels time)
Topic description
Expected Outcome:
Background
Novel and emerging transformative (disruptive) innovations[1] are a concept which applies to innovations that make products and services more accessible and affordable, thereby making them available to a larger population. These interventions or innovations should offer more accessible, cost-effective, and efficient solutions and be preferably beyond proof of concept. Funding under this topic will be aimed at encouraging research and innovations targeting those overlooked segments in R&D and products implementation delivering more patient-centric and context-specific delivery forms, improved functionality and new products and systems at a lower price or overall value-for-money advantage when combined with existing interventions.
Expected Outcome
This topic aims at supporting activities that contribute to one or several of the expected outcomes for this call. Proposals under this topic should aim to deliver results that are contributing to at least one of the following expected outcomes:
- Generate beyond proof of concept data with innovative ideas or inventions that will improve the uptake, adherence or implementation of preventative/treatment/diagnostic solutions;
- Progress an innovative approach that makes products and services (more) accessible and affordable to commercially unattractive markets or serves vulnerable populations in SSA;
- Progress an innovative approach that addresses community-driven and trusted demand for new or repurposed tools, including those needed by hard-to-reach communities;
- Deliver innovative technologies which can generate accelerated cross-disease solutions, including communicable disease specific solutions;
- Repurpose or extend the use of an existing preventative/treatment/diagnostic intervention.
[1] Disruptive Technologies: Catching the Wave (hbr.org)
Scope:
Scope
The objective of the topic is to progress a development which meet at least one of the below:
- Innovations in R&D or products implementation focusing on new or improvement of existing medicinal products and delivery systems of new or improved medical technologies within the health systems. This may include but not limited to use of new technologies;
- Development of a new intervention or improvements of an existing intervention for age-appropriate formulations or underserved populations. This may include but not limited to development of paediatric or geriatric formulations generating data for patients with co-morbidities;
- Development of tools to improve the affordability or accessibility of preventative/ treatment/ diagnostic solutions in SSA or specific vulnerable populations as relevant. This may include but not limited to development of thermostable or humid resistant formulations, lower cost of goods, dose sparing approaches;
- Accelerate the development of delivery systems which will improve the efficacy or uptake of the preventative/treatment/diagnostic solutions in SSA. This may include but not limited to assessing different route of administration ensuring easier access, new or improved devices or equipment ensuring higher efficacy or uptake, etc;
- Leverage existing data to repurpose and expand the use of the preventative/ treatment/ diagnostic intervention. This may include but not limited to using well-established safety and pharmacological data from its use in one disease area into the infectious disease field in the scope of the Global Health EDCTP3.
Scope includes infectious diseases in scope of the Global Health EDCTP3 including HIV/AIDS. Proposalsare to generate beyond proof-of-concept data.
Out of scope: infectious diseases not in scope of the Global Health EDCTP3, potential solutions tacklingchronic diseases potentially caused by infections, and non-communicable diseases.
Applicants are invited to address the following in the proposals:
- Proposals should clearly define the challenge or unmet need they are addressing. Applicants must provide a rationale explaining why this gap has not yet been successfully addressed and how their innovation will overcome these barriers. The proposal should highlight the unique value proposition and potential transformative impact of the innovation. Special attention should be paid to how the innovation serves vulnerable or underserved populations as relevant.
- Proposals should present a comprehensive strategy for engaging communities and relevant stakeholders, most notably (local) key opinion leaders, researchers, health care professionals, policy makers, regulatory bodies, public health authorities, supply chain actors and end-users. Applicants should provide methodologies for translating research findings into public health practice and policy guidelines when relevant.
- For innovations with a technological component, applicants should outline a clear roadmap for technology transfer, ensuring that the innovation can be scaled sustained by local or regional entities. The roadmap should include productisation pathways outlining how the innovation will transition from development to practical application. Proposals should also encourage local ownership by ensuring that the necessary skills and capacity building for long-term sustainability are embedded in the project.
- Proposals should clearly describe the desired target product profile. Applicants need to concisely describe any prior relevant research findings and explain how the proposal builds on available data (including data generated in scope of earlier EDCTP programmes if available). Full details of the development milestones, including specific go/no-go criteria for the implementation of the proposed clinical trial(s) must be included, as well as specific plans for the subsequent regulatory approval process, which should aim at obtaining relevant market authorisation, and an access strategy that will allow patients in low-resource settings to access the final product.
- Where relevant, proposals should demonstrate early engagement with regulatory bodies and manufacturers to facilitate the timely translation of innovations into affordable, regionally available products. Where possible, collaboration and coordination with the Team Europe Initiative on Manufacturing and Access to Vaccines, medicines and health products (TEI-MAV+) or similar African initiative is encouraged. The applicants could show, for example, willingness to enter into technology transfer agreements with African counterparts - including the provision of patents, technical knowledge and know-how -, or early engagement with regulators or with African manufacturers to support the translation into affordable products adapted to the regional market.
Applicants are reminded of the expectation that proposals should come from research consortia with a strong representation of institutions and researchers from sub-Saharan African countries, including involvement of Franco/Lusophone countries, if possible. Collaboration with other international research groups with relevant experience is very much encouraged. Applicants are also reminded of the expectation of reaching out to institutions/organisations in countries with high disease burden but with relatively lower research capacities.
General conditions
1. Admissibility Conditions: Proposal page limit and layout
described in Annex A and Annex E of the Horizon Europe Work Programme General Annexes.
Proposal page limits and layout: described in Part B of the Application Form available in the Submission System.
DELETE ME Please add hyperlinks as embedded links where needed (underscored text). Send the call document through the document publication form to receive the hyperlink within 2 business days max. DELETE ME
2. Eligible Countries
described in Annex B of the Work Programme General Annexes.
A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide.
3. Other Eligible Conditions
The conditions are described in General Annex B except for the specific conditions for the Global Health EDCTP3 JU funding as regards entities eligible for funding and consortium composition, the specific rule for countries where the coordinator may be established and the obligation to designate a scientific project leader as below.
Specific conditions replacing the relevant sections in General Annex B to the Horizon Europe Work Programmes.
A. Entities eligible for funding
This section applies to both Research and Innovation Actions (RIA) and Coordination and Support Actions (CSA).
To become a beneficiary, legal entities must be eligible for funding. To be eligible for funding, applicants must be established in one of the following countries:
- The Member States of the European Union, including their outermost regions: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden;
- The Overseas Countries and Territories (OCTs) linked to the Member States: Aruba (NL), Bonaire (NL), Curação (NL), French Polynesia (FR), French Southern and Antarctic Territories (FR), Greenland (DK), New Caledonia (FR), Saba (NL), Saint Barthélemy (FR), Sint Eustatius (NL), Sint Maarten (NL), St. Pierre and Miquelon (FR), Wallis and Futuna Islands (FR);
- Countries associated to Horizon Europe[1]: Albania, Armenia, Bosnia and Herzegovina, Canada, Faroe Islands, Georgia, Iceland, Israel, Kosovo[2], Moldova, Montenegro, New Zealand (associated to Pillar II 'Global Challenges and European Industrial Competitiveness' as from the Work Programmes 2023 onwards, including for the institutionalised European partnerships), North Macedonia, Norway, Serbia, Tunisia, Turkey, Ukraine, United Kingdom;
- Until association agreements start producing legal effects either through provisional application or their entry into force, transitional arrangements apply. The transitional arrangements apply, at the time of the adoption of this Work Programme, with regard to the following countries and legal entities established in these countries, with which association negotiations are being processed or where association is imminent):Morocco.
- The following countries which are constituent states of the EDCTP Association [3]: Benin, Burkina Faso, Cameroon, Côte d’Ivoire, Democratic Republic of the Congo, Ethiopia, Eswatini, Gabon, The Gambia, Ghana, Guinea-Bissau, Guinea-Conakry, Kenya, Liberia, Malawi, Mali, Mozambique, Niger, Nigeria, Republic of the Congo, Rwanda, Senegal, Sierra Leone, Somalia, South Africa, Tanzania, Uganda, Zambia, Zimbabwe.
Legal entities which are established in countries not listed above will be eligible for funding if provided for in the specific call/topic conditions, or if their participation is considered essential for implementing the action by the granting authority.
Entities established in low- and middle-income countries that are not members of the EDCTP Association and listed in the Horizon Europe List of Participating Countries on the Funding & Tenders Portal [4] are not eligible for funding unless the specific country in which the entity is established, is associated to Horizon Europe or if the participation of the entity is considered essential for implementing the action by the granting authority.
B. Consortium composition
Unless otherwise provided for in the specific call conditions, for all actions, due to the policy objectives of the Global Health EDCTP3 JU, legal entities forming a consortium are eligible to participate in actions under the programme provided that the consortium includes as beneficiaries:
- At least three legal entities independent from each other and each established in a different country, where legal entities are eligible to receive funding;
- At least one independent legal entity established in a Member State, or in an associated country to Horizon Europe that is a member of the EDCTP Association; and
- At least one independent legal entity established in a sub-Saharan African country that is a member of the EDCTP Association.
This condition applies to both Research and Innovation Actions (RIA) and Coordination and SupportActions (CSA).
For the two CSA topics, i.e. topic HORIZON-JU-GH-EDCTP3-2025-02-FELLOW-01-two-stage and topic HORIZON-JU-GH-EDCTP3-2025-03-NETWORKS-01-two-stage - according to which the EDCTP Association is obligatorily part of the consortium as coordinator, the EDCTP Association must not be counted as one of the three independent legal entities necessary to ensure the eligibility of the consortium composition.
Specific cases:
Affiliated entities — Affiliated entities are eligible for funding if they are established in one of the countries listed above, or in a country identified in the specific call/topic conditions.
Associated partners — Entities not eligible for funding and therefore not able to participate as beneficiaries or affiliated entities (i.e. entities which participate in the action without signing the grant agreement, and without the right to charge costs or claim contributions) are allowed, subject to any conditions regarding associated partners set out in the specific call conditions.
International organisations – International European research organisations are eligible to receive funding. Other international organisations are not eligible to receive funding unless their participation is considered essential for implementing the action by the granting authority. International organisations with headquarters in a Member State or associated country are eligible to receive funding when provided for in the specific call conditions.
Specific rules regarding legal entities that may be the coordinator of an indirect action
In accordance with Article 110(2) of the Council Regulation 2021/2085 establishing the Joint Undertakings under Horizon Europe[5], where entities established in a third country without an agreement to protect the financial interests of the Union participate with funding in an indirect action, the coordinator of the indirectaction must be established in a Member State or associated country, or South Africa.
Scientific project leader
If the coordinator is not established in a country in SSA (please see previous paragraph), the designation of a scientific project leader established in a SSA country member of the EDCTP Association with the roles as described below is mandatory. A work package on ‘scientific project leadership’ must be included in the proposals and budget needs to be provided for this activity. The scientific project leader oversees the project scientific governance and leadership. For this purpose, proposals must include a work package where the details of scientific project leadership are laid down. The scientific project leader should indicatively perform the following tasks:
- During the call for proposals and selection process, coordinate meetings on and drafting of the full project proposal;
- Work with the coordinator and other beneficiaries on the drafting and negotiation of the consortium agreement and other legal agreements among the beneficiaries;
- Act as the key contact point for the Global Health EDCTP3 JU regarding all scientific action governance issues, steer and provide oversight in the development of the scientific actions, without prejudice to the tasks entrusted directly to the coordinator as per the Model Grant Agreement;
- Support and collaborate with the coordinator on its monitoring activities and the adoption of appropriate internal measures, to ensure that beneficiaries are fulfilling their obligations regarding budget, timeline, deliverables, and scientific quality;
- Review the action’s deliverables and reports before their submission by the coordinator;
- Lead the work packages(s) related to the tasks of scientific project leadership.
Annex 1 to the grant agreement and the consortium agreement should address the relationship of the scientific project leader with the coordinator regarding their respective tasks, for example sharing of the information received from or sent to the Global Health EDCTP3 JU on all issues of interest for the proper scientific management of the action.
[1] The list is correct at the time of adoption of this work programme. Please see the Horizon Europe List of Participating Countries on the Funding & Tenders Portal for up-to-date information on the current list and on the position for Associated Countries: https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/list-3rd-country-participation_horizon-euratom_en.pdf
[2] This designation is without prejudice to positions on status and is in line with UNSCR 1244/1999 and the ICJ Opinion on the Kosovo declaration of independence.
[3] The list is correct at the time of adoption of this work programme. For an update, please check the EDCTP Association website www.edctp.org
[4] Horizon Europe List of Participating Countries on the Funding & Tenders Portal https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/common/guidance/list-3rd-country-participation_horizon-euratom_en.pdf
[5] Council Regulation (EU) 2021/2085 of 19 November 2021 establishing the Joint Undertakings under Horizon Europe and repealing Regulations (EC) No 219/2007, (EU) No 557/2014, (EU) No 558/2014, (EU) No 559/2014, (EU) No 560/2014, (EU) No 561/2014 and (EU) No 642/2014. OJ L 427, 30.11.2021, p. 17–119; Regulation - 2021/2085 - EN - EUR-Lex (europa.eu).
described in Annex B of the Work Programme General Annexes.
4. Financial and operational capacity and exclusion
described in Annex C of the Work Programme General Annexes.
5a. Evaluation and award: Award criteria, scoring and thresholds
are described in Annex D of the Work Programme General Annexes.
5b. Evaluation and award: Submission and evaluation processes
Specific conditions related to Scores and weighting
Replacing the scores and weighting section in General Annex D to the Horizon Europe Work Programmes as regards second stage of two-stage evaluations, for both Research and Innovation Actions (RIA) and Coordination and Support Actions (CSA)
Evaluation scores will be awarded for the criteria, and not for the different aspects listed in the table. For full applications, each criterion will be scored out of 5. The threshold for individual criteria 1 (Excellence) and 2 (Impact) will be 4 and for criterion 3 (Quality and Efficiency of the implementation) will be 3. The overall threshold, applying to the sum of the three individual scores, will be 12.
Proposals that pass the individual threshold and the overall threshold will be considered for funding, within the limits of the available call budget. Other proposals will be rejected.
Nota bene, for the first stage of the two-stage evaluation of both RIAs and CSAs, the scores and weightingas indicated in Annex D of the General Annexes of the Horizon Europe work programme 2023/2025 apply.
are described in Annex F of the Work Programme General Annexes and the Online Manual.
5c. Evaluation and award: Indicative timeline for evaluation and grant agreement
described in Annex F of the Work Programme General Annexes.
6. Legal and financial set-up of the grants
Also in line with Article 114 of the Council Regulation 2021/2085, participants will be subject to the following additional exploitation obligations:
- Participants must – up to four years after the end of the action (see Data Sheet, Point 1) – use their best efforts to ensure that resulting health technologies and services will be broadly available and accessible, as soon as possible and at fair and reasonable conditions. In this respect, if, despite a participants’ best efforts, the results are not exploited within one year after the end of the action, participants must (unless otherwise agreed in writing with the granting authority) use the Horizon Results Platform to find interested parties to exploit the results.
- In case the participants cannot fulfil the preceding obligation, the participants must (if requested by the granting authority) grant non- exclusive licences - under fair and reasonable conditions - to their results to legal entities that commit to rapidly and broadly exploiting the resulting health technologies and services and ensure that they are broadly available and accessible, as soon as possible and at fair and reasonable conditions.
- In case of transfer of the ownership or licensing of results, participants must pass on such additional exploitation obligations to the legal entities exploiting the results.
- For up to four years after the action (see Data Sheet, Point 1), the funding body must be informed every year about the status of the development of the product and any other exploitation of the results through an annual report that is due on each anniversary of the end of the grant agreement.
Implementing the provision on affordable access as defined in Article 114 of the Council Regulation 2021/2085 establishing52, grants awarded under this topic will have to include in their Plan for the exploitation and dissemination of results including communication activities to be submitted during the project as a deliverable also the following:
Access plan
Participants must include in their Plan for the exploitation and dissemination of results an appropriate and proportionate access plan that demonstrates their strategies to ensure that the products and services that they develop based or partly based on the results of clinical studies undertaken by their project are affordable, available and accessible to the public (market and end-users) at fair and reasonable conditions. This covers registration targets, plans to meet demand, flexible approaches to IP, engagement with regulators and manufacturers where relevant and other strategies that reflect ability to pay and ensures that economic barriers to access are low. In addition, participants should add, if relevant, as part of the plan, an outline on how to achieve the optimal use of an intervention including, for example, how to avoid irrational use, overuse or abuse (e.g. antimicrobials).
Additionally to any updates during the project, a final version of the Plan for the exploitation and dissemination of results including the above access plan, must also be submitted with the final report of the project.
described in Annex G of the Work Programme General Annexes.
Specific conditions
JU right to object to transfer/exclusive licensing
The Global Health EDCTP3 JU may, up to 4 years after the end of the action, object to a transfer of ownership or to the exclusive licensing of results, as set out in the specific provision of Annex 5 of the Model Grant Agreement. In addition, in accordance with Article 24(3) of Council Regulation 2021/2085 establishing the Joint Undertakings under Horizon Europe [1] and the Model Grant Agreement, the right toobject applies also to participants that have not received funding from the JU.
[1]Council Regulation (EU) 2021/2085 of 19 November 2021 establishing the Joint Undertakings under Horizon Europe and repealing Regulations (EC) No 219/2007, (EU) No 557/2014, (EU) No 558/2014, (EU) No 559/2014, (EU) No 560/2014, (EU) No 561/2014 and (EU) No 642/2014; OJ L 427, 30.11.2021, p. 17.
Annual Work Programme 2025
Global Health EDCTP3 Calls for proposals
Application and evaluation forms and model grant agreement (MGA):
Application form templates — the application form specific to this call is available in the Submission System
Note: despite blind evaluation being mentioned in the standard application form for stage 1 proposals, available in the Funding and Tenders Portal (at the stage of adoption of this Work Programme), please note that this call is not part of the ‘blind evaluation pilot’, therefore no anonymisation is required for stage 1proposals of the two-stage calls.
Standard application form (HE RIA IA Stage 1)
Evaluation form templates — will be used with the necessary adaptations
Standard evaluation form (HE RIA, IA and CSA Stage 1)
Guidance
HE Programme Guide
Model Grant Agreements (MGA)
HE MGA
Call-specific instructions
Information on financial support to third parties (HE)
Information on clinical studies (HE)
Additional documents:
HE Main Work Programme 2023–2025 – 1. General Introduction
HE Main Work Programme 2023–2025 – 4. Health
HE Main Work Programme 2023–2025 – 13. General Annexes
HE Programme Guide
HE Framework Programme 2021/695
HE Specific Programme Decision 2021/764
EU Financial Regulation 2024/2509
Rules for Legal Entity Validation, LEAR Appointment and Financial Capacity Assessment
EU Grants AGA — Annotated Model Grant Agreement
Funding & Tenders Portal Online Manual
Funding & Tenders Portal Terms and Conditions
Funding & Tenders Portal Privacy Statement
Start submission
The submission system is planned to be opened on the date stated on the topic header.
Get support
Online Manual is your guide on the procedures from proposal submission to managing your grant.
Horizon Europe Programme Guide contains the detailed guidance to the structure, budget and political priorities of Horizon Europe.
Funding & Tenders Portal FAQ – find the answers to most frequently asked questions on submission of proposals, evaluation and grant management.
Research Enquiry Service – ask questions about any aspect of European research in general and the EU Research Framework Programmes in particular.
National Contact Points (NCPs) – get guidance, practical information and assistance on participation in Horizon Europe. There are also NCPs in many non-EU and non-associated countries (‘third-countries’).
Enterprise Europe Network – contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding.
IT Helpdesk – contact the Funding & Tenders Portal IT helpdesk for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.
European IPR Helpdesk assists you on intellectual property issues.
CEN-CENELEC Research Helpdesk and ETSI Research Helpdesk – the European Standards Organisations advise you how to tackle standardisation in your project proposal.
The European Charter for Researchers and the Code of Conduct for their recruitment – consult the general principles and requirements specifying the roles, responsibilities and entitlements of researchers, employers and funders of researchers.
Partner Search help you find a partner organisation for your proposal.
Similar grants
By Locations
Funding agency:
EC
Status:
awarded
Location:
EU 27
Funding agency:
EC
Status:
awarded
Location:
EU 27
By Sectors
Funding agency:
EC
Status:
awarded
Location:
Kosovo
Funding agency:
Horizon 2020
Status:
awarded
Location:
EU 27, Switzerland
grant Background
About the Funding Agency
Horizon Europe will incorporate research and innovation missions to increase the effectiveness of funding by pursuing clearly defined targets.
The Commission has engaged policy experts to develop studies, case studies and reports on how a mission-oriented policy approach will work.
Mission areas
5 mission areas have been identified, each with a dedicated mission board and assembly. The board and assembly help specify, design and implement the specific missions which will launch under Horizon Europe in 2021.
- Adaptation to climate change including societal transformation
- Cancer
- Climate-neutral and smart cities
- Healthy oceans, seas, coastal and inland waters
- Soil health and food
About the Sectors
Health
Covers healthcare services, public health systems, and activities aimed at promoting physical and mental well-being.
Key areas:
- Healthcare services and facilities
- Public health and disease prevention
- Medical equipment, supplies, and services
Research & Innovation
Focuses on collecting data, generating new knowledge, and applying it to develop improved methods, technologies, products, and solutions across sectors.
Key areas:
- Scientific research, studies, and investigations
- Innovation programs and applied R&D initiatives
- Technology development
- Space-related research and exploration themes
Frequently Asked Questions
Haven't found what you're looking for? Get in touch with us using our contact page.
Where can I find international grant opportunities?
DevelopmentAid collects grant opportunities from bilateral donors, multilateral agencies, foundations, and international organizations in one centralized platform.
Who can apply for grants listed on DevelopmentAid?
Grants are typically open to NGOs, civil society organizations, research institutions, public entities, and sometimes private organizations or consortia.
Does DevelopmentAid help with grant applications?
DevelopmentAid does not write or submit applications, but it provides access to full call details, guidelines, deadlines, and donor information needed to apply.